{"transactions":[{"id":725225,"issuer":{"id":7406,"kind":"organization","name":"Context Therapeutics Inc."},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T20:20:18.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer."}],"balance_after":45000,"derivative":{"exercise_price":0.576,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001628280-26-045778","document":"wk-form4_1782505215.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1639637/000162828026045778/wk-form4_1782505215.xml","form_type":"4"}},{"id":819042,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T22:22:31.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the one year period beginning March 31, 2026."}],"balance_after":75000,"derivative":{"exercise_price":0.615,"expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001628280-26-023358","document":"wk-form4_1775168549.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026023358/wk-form4_1775168549.xml","form_type":"4"}},{"id":914145,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-10T01:54:50.000Z","date":"2026-02-06","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the one-year period beginning January 19, 2026."}],"balance_after":35000,"derivative":{"exercise_price":0.82,"expiration_date":"2036-02-06","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001628280-26-006625","document":"wk-form4_1770688487.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026006625/wk-form4_1770688487.xml","form_type":"4"}},{"id":1110382,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:05:23.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":50000,"derivative":{"exercise_price":0.503,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-017374","document":"form4-06162025_040615.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925017374/form4-06162025_040615.xml","form_type":"4"}},{"id":1110381,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-16T20:05:23.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit (\"RSU\") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\")) through such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":102100,"source":{"system":"sec-edgar","filing":"0001415889-25-017374","document":"form4-06162025_040615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925017374/form4-06162025_040615.xml","form_type":"4"}},{"id":1112866,"issuer":{"id":7406,"kind":"organization","name":"Context Therapeutics Inc."},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-12T21:27:03.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":123500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable on the earlier of (i) June 12, 2026 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2026 annual meeting of stockholders, subject to continued service with the Issuer."}],"balance_after":123500,"derivative":{"exercise_price":0.653,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":123500},"source":{"system":"sec-edgar","filing":"0001842952-25-000076","document":"wk-form4_1749763615.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1639637/000184295225000076/wk-form4_1749763615.xml","form_type":"4"}},{"id":1242520,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-26T22:45:16.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the one year period beginning February 21, 2025."}],"balance_after":35000,"derivative":{"exercise_price":2.89,"expiration_date":"2035-02-25","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001516551-25-000012","document":"wk-form4_1740609908.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655125000012/wk-form4_1740609908.xml","form_type":"4"}},{"id":1352337,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2024-11-25T21:38:58.000Z","date":"2024-11-21","kind":"grant","planned":false,"acquired":true,"shares":18641,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options shall vest one year from date of grant."}],"balance_after":18641,"derivative":{"exercise_price":8.24,"expiration_date":"2034-11-21","underlying":"Common Shares","underlying_shares":18641},"source":{"system":"sec-edgar","filing":"0001600620-24-000126","document":"wk-form4_1732570731.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000126/wk-form4_1732570731.xml","form_type":"4"}},{"id":1352336,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-11-25T21:38:58.000Z","date":"2024-11-21","kind":"grant","planned":false,"acquired":true,"shares":12135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of Restricted Stock Units (RSUs) payable solely in common shares of the Issuer. The shares subject to the RSUs shall vest one year from date of grant."}],"balance_after":24807,"source":{"system":"sec-edgar","filing":"0001600620-24-000126","document":"wk-form4_1732570731.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000126/wk-form4_1732570731.xml","form_type":"4"}},{"id":1368197,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-11-13T00:20:36.000Z","date":"2024-11-08","kind":"exercise","planned":false,"acquired":false,"shares":17913,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vested one year from date of grant and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vested one year from date of grant and have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":17913},"source":{"system":"sec-edgar","filing":"0001600620-24-000114","document":"wk-form4_1731457229.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000114/wk-form4_1731457229.xml","form_type":"4"}},{"id":1368196,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-13T00:20:36.000Z","date":"2024-11-11","kind":"sale","planned":false,"acquired":false,"shares":5241,"price":8.43,"value":44181.63,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.37 to $8.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":12672,"source":{"system":"sec-edgar","filing":"0001600620-24-000114","document":"wk-form4_1731457229.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000114/wk-form4_1731457229.xml","form_type":"4"}},{"id":1368195,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-13T00:20:36.000Z","date":"2024-11-08","kind":"exercise","planned":false,"acquired":true,"shares":17913,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":17913,"source":{"system":"sec-edgar","filing":"0001600620-24-000114","document":"wk-form4_1731457229.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000114/wk-form4_1731457229.xml","form_type":"4"}},{"id":1379293,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-31T00:28:15.000Z","date":"2024-10-28","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the one year period beginning October 28, 2024."}],"balance_after":70000,"derivative":{"exercise_price":5.15,"expiration_date":"2034-10-27","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001516551-24-000098","document":"wk-form4_1730334489.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655124000098/wk-form4_1730334489.xml","form_type":"4"}},{"id":1413486,"issuer":{"id":7406,"kind":"organization","name":"Context Therapeutics Inc."},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-09-05T12:15:04.000Z","date":"2024-09-04","kind":"grant","planned":false,"acquired":true,"shares":19315,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable on the earlier of (i) June 13, 2025 or (ii) the Issuer's 2025 annual meeting of stockholders, subject to continued service with the Issuer."}],"balance_after":19315,"derivative":{"exercise_price":2.43,"expiration_date":"2034-09-03","underlying":"Common Stock","underlying_shares":19315},"source":{"system":"sec-edgar","filing":"0001842952-24-000079","document":"wk-form4_1725538497.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1639637/000184295224000079/wk-form4_1725538497.xml","form_type":"4"}},{"id":1458736,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2024-07-05T12:59:09.000Z","date":"2024-07-02","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in equal monthly installments over the one year period from the date of grant."}],"balance_after":40000,"derivative":{"exercise_price":7.56,"expiration_date":"2034-07-01","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001516551-24-000068","document":"wk-form4_1720184343.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655124000068/wk-form4_1720184343.xml","form_type":"4"}},{"id":1488919,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:26:31.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":50000,"derivative":{"exercise_price":0.5676,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-24-015762","document":"form4-06062024_080627.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588924015762/form4-06062024_080627.xml","form_type":"4"}},{"id":1488918,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-06T20:26:31.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit (\"RSU\") grant that will fully vest on the earlier of (a) June 4, 2025 or (b) the day prior to the 2025 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\")) through such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":77100,"source":{"system":"sec-edgar","filing":"0001415889-24-015762","document":"form4-06062024_080627.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588924015762/form4-06062024_080627.xml","form_type":"4"}},{"id":1800465,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-08-21T20:19:48.000Z","date":"2023-08-18","kind":"grant","planned":false,"acquired":true,"shares":28959,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in twelve equal installments commencing on September 18, 2023."}],"balance_after":28959,"derivative":{"exercise_price":9.49,"expiration_date":"2033-08-18","underlying":"Common Stock","underlying_shares":28959},"source":{"system":"sec-edgar","filing":"0001600620-23-000034","document":"wk-form4_1692649179.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062023000034/wk-form4_1692649179.xml","form_type":"4"}},{"id":1800464,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-08-21T20:19:48.000Z","date":"2023-08-18","kind":"grant","planned":false,"acquired":true,"shares":17913,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest one year from date of grant and have no expiration date. Vested shares will be delivered on August 18, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest one year from date of grant and have no expiration date. Vested shares will be delivered on August 18, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest one year from date of grant and have no expiration date. Vested shares will be delivered on August 18, 2024."}],"balance_after":17913,"derivative":{"underlying":"Common Stock","underlying_shares":17913},"source":{"system":"sec-edgar","filing":"0001600620-23-000034","document":"wk-form4_1692649179.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062023000034/wk-form4_1692649179.xml","form_type":"4"}},{"id":1855488,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-14T23:02:37.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting."}],"balance_after":20500,"derivative":{"exercise_price":2.54,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001209191-23-037192","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1639637/000120919123037192/doc4.xml","form_type":"4"}},{"id":1868081,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-05T20:52:07.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":27750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":27750,"derivative":{"exercise_price":1.11,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":27750},"source":{"system":"sec-edgar","filing":"0001209191-23-034407","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919123034407/doc4.xml","form_type":"4"}},{"id":1868080,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T20:52:07.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":13900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will fully vest on the earlier of (a) June 1, 2024 or (b) the day prior to the 2024 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\")) through such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":52100,"source":{"system":"sec-edgar","filing":"0001209191-23-034407","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919123034407/doc4.xml","form_type":"4"}},{"id":2035056,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-02-02T23:35:56.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date."}],"balance_after":225000,"derivative":{"exercise_price":0.94,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001209191-23-006401","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1639637/000120919123006401/doc4.xml","form_type":"4"}},{"id":2233645,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-13T22:16:02.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":14501,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting."}],"balance_after":14501,"derivative":{"exercise_price":8.45,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":14501},"source":{"system":"sec-edgar","filing":"0000899243-22-022251","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1639637/000089924322022251/doc4.xml","form_type":"4"}},{"id":2252710,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-05-27T21:37:29.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":170354,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares vest monthly, subject to continued service."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 19, 2022, the Issuer completed acquisition (the \"Merger\") of Novosteo Inc. (\"Novosteo\"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the \"Merger Agreement\"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer."}],"balance_after":194690,"source":{"system":"sec-edgar","filing":"0001209191-22-032677","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1639637/000120919122032677/doc4a.xml","form_type":"4/A","original_submission_date":"2022-05-23"}},{"id":2255808,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T17:26:54.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":48542,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."}],"balance_after":0,"derivative":{"exercise_price":4.42,"underlying":"Common Stock","underlying_shares":48542},"source":{"system":"sec-edgar","filing":"0000899243-22-019793","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019793/doc4.xml","form_type":"4"}},{"id":2255807,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T17:26:54.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":58246,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."}],"balance_after":0,"derivative":{"exercise_price":2.73,"underlying":"Common Stock","underlying_shares":58246},"source":{"system":"sec-edgar","filing":"0000899243-22-019793","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019793/doc4.xml","form_type":"4"}},{"id":2255806,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T17:26:54.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":46729,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."}],"balance_after":0,"derivative":{"exercise_price":2.92,"underlying":"Common Stock","underlying_shares":46729},"source":{"system":"sec-edgar","filing":"0000899243-22-019793","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019793/doc4.xml","form_type":"4"}},{"id":2255805,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T17:26:54.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."}],"balance_after":0,"derivative":{"exercise_price":3.72,"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-22-019793","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019793/doc4.xml","form_type":"4"}},{"id":2255804,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-26T17:26:54.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":25452,"price":5.6,"value":142531.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Each Company restricted stock unit (\"Company RSU\") means any restricted stock unit granted under the Company Equity Plan. At the Effective Time, each Company RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the \"Company\"),  Halozyme Therapeutics, Inc., a Delaware corporation (\"Parent\"), and Atlas Merger Sub, Inc., a Delaware corporation (\"Purchaser\") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of May 24, 2022 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the \"Merger Consideration\") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-019793","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019793/doc4.xml","form_type":"4"}},{"id":2255803,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-26T17:26:54.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":54193,"price":5.6,"value":303480.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the \"Company\"),  Halozyme Therapeutics, Inc., a Delaware corporation (\"Parent\"), and Atlas Merger Sub, Inc., a Delaware corporation (\"Purchaser\") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of May 24, 2022 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the \"Merger Consideration\") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-019793","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019793/doc4.xml","form_type":"4"}},{"id":2259410,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-05-24T00:24:15.000Z","date":"2022-05-23","kind":"grant","acquired":true,"shares":1365449,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years."}],"balance_after":1365449,"derivative":{"exercise_price":2.98,"expiration_date":"2032-05-22","underlying":"Common Stock","underlying_shares":1365449},"source":{"system":"sec-edgar","filing":"0001209191-22-031508","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1639637/000120919122031508/doc4.xml","form_type":"4"}},{"id":2259409,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-05-24T00:24:15.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":151799,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in the Merger in exchange for an employee stock option to acquire 1,667,000 shares of Novosteo common stock for $0.05 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years."}],"balance_after":151799,"derivative":{"exercise_price":0.55,"expiration_date":"2032-03-27","underlying":"Common Stock","underlying_shares":151799},"source":{"system":"sec-edgar","filing":"0001209191-22-031508","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1639637/000120919122031508/doc4.xml","form_type":"4"}},{"id":2259408,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-05-24T00:24:15.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":24336,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 19, 2022, the Issuer completed acquisition (the \"Merger\") of Novosteo Inc. (\"Novosteo\"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the \"Merger Agreement\"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer."}],"balance_after":24336,"source":{"system":"sec-edgar","filing":"0001209191-22-031508","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1639637/000120919122031508/doc4.xml","form_type":"4"}},{"id":2267328,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-17T22:15:23.000Z","date":"2022-05-16","kind":"grant","acquired":true,"shares":29002,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in three equal installments from the date of grant."}],"balance_after":29002,"derivative":{"exercise_price":6.54,"expiration_date":"2032-05-15","underlying":"Common Stock","underlying_shares":29002},"source":{"system":"sec-edgar","filing":"0000899243-22-018449","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1639637/000089924322018449/doc4.xml","form_type":"4"}},{"id":2366630,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-01T22:14:00.000Z","date":"2022-02-25","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":25000,"derivative":{"exercise_price":5.9,"expiration_date":"2032-02-24","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-22-014157","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919122014157/doc4.xml","form_type":"4"}},{"id":2366629,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-01T22:14:00.000Z","date":"2022-02-25","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\")) through such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":38200,"source":{"system":"sec-edgar","filing":"0001209191-22-014157","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919122014157/doc4.xml","form_type":"4"}},{"id":2500511,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:09:56.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":3222,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":115.53,"underlying":"Common Stock","underlying_shares":3222},"source":{"system":"sec-edgar","filing":"0001104659-21-142277","document":"tm2133601-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142277/tm2133601-10_4seq1.xml","form_type":"4"}},{"id":2500510,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:09:56.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":4085,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":52.99,"underlying":"Common Stock","underlying_shares":4085},"source":{"system":"sec-edgar","filing":"0001104659-21-142277","document":"tm2133601-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142277/tm2133601-10_4seq1.xml","form_type":"4"}},{"id":2500509,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:09:56.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":3750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":41.64,"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001104659-21-142277","document":"tm2133601-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142277/tm2133601-10_4seq1.xml","form_type":"4"}},{"id":2500508,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:09:56.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":1875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":40.61,"underlying":"Common Stock","underlying_shares":1875},"source":{"system":"sec-edgar","filing":"0001104659-21-142277","document":"tm2133601-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142277/tm2133601-10_4seq1.xml","form_type":"4"}},{"id":2500507,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:09:56.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":35.34,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-21-142277","document":"tm2133601-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142277/tm2133601-10_4seq1.xml","form_type":"4"}},{"id":2500506,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-22T09:09:56.000Z","date":"2021-11-19","kind":"other","acquired":false,"shares":1622,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. (\"Parent\"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 19, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. (\"Parent\"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 19, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. (\"Parent\"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 19, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-21-142277","document":"tm2133601-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142277/tm2133601-10_4seq1.xml","form_type":"4"}},{"id":2670762,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-14T18:27:22.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":48542,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest and become exercisable one year from the grant date."}],"balance_after":48542,"derivative":{"exercise_price":4.42,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":48542},"source":{"system":"sec-edgar","filing":"0001209191-21-040340","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121040340/doc4.xml","form_type":"4"}},{"id":2670761,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-14T18:27:22.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":25452,"price":4.42,"value":112497.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest one year from the grant date."}],"balance_after":79645,"source":{"system":"sec-edgar","filing":"0001209191-21-040340","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121040340/doc4.xml","form_type":"4"}},{"id":2718230,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-05-11T20:30:11.000Z","date":"2021-05-07","kind":"tax_withholding","acquired":false,"shares":305,"price":60.85,"value":18559.25,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of common stock withheld to pay taxes upon vest of restricted stock units granted under the company's stock incentive plan, as amended and restated."}],"balance_after":11888,"source":{"system":"sec-edgar","filing":"0001367644-21-000081","document":"wf-form4_162076498795882.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764421000081/wf-form4_162076498795882.xml","form_type":"4"}},{"id":2757373,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-04-05T20:17:30.000Z","date":"2021-04-05","kind":"exercise","acquired":false,"shares":2050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of common stock underlying this stock option award vested in full on the one year anniversary of the grant date."}],"balance_after":4085,"derivative":{"exercise_price":52.99,"expiration_date":"2030-01-22","underlying":"Common Stock","underlying_shares":2050},"source":{"system":"sec-edgar","filing":"0001179110-21-004223","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004223/edgar.xml","form_type":"4"}},{"id":2757372,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-04-05T20:17:30.000Z","date":"2021-04-05","kind":"exercise","acquired":false,"shares":1875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of common stock underlying this stock option award vested in full on the one year anniversary of the grant date."}],"balance_after":3750,"derivative":{"exercise_price":41.64,"expiration_date":"2029-01-25","underlying":"Common Stock","underlying_shares":1875},"source":{"system":"sec-edgar","filing":"0001179110-21-004223","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004223/edgar.xml","form_type":"4"}},{"id":2757371,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-04-05T20:17:30.000Z","date":"2021-04-05","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of common stock underlying this stock option award vested in equal quarterly installments over the first three years after the grant."}],"balance_after":10000,"derivative":{"exercise_price":35.34,"expiration_date":"2027-11-15","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001179110-21-004223","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004223/edgar.xml","form_type":"4"}},{"id":2757370,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-05T20:17:30.000Z","date":"2021-04-05","kind":"sale","acquired":false,"shares":641,"price":141.15,"value":90477.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.01 to $141.34 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":1622,"source":{"system":"sec-edgar","filing":"0001179110-21-004223","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004223/edgar.xml","form_type":"4"}},{"id":2757369,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-05T20:17:30.000Z","date":"2021-04-05","kind":"sale","acquired":false,"shares":11223,"price":140.13,"value":1572678.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.00 to $140.92 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":2263,"source":{"system":"sec-edgar","filing":"0001179110-21-004223","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004223/edgar.xml","form_type":"4"}},{"id":2757368,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-05T20:17:30.000Z","date":"2021-04-05","kind":"exercise","acquired":true,"shares":2050,"price":52.99,"value":108629.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":13486,"source":{"system":"sec-edgar","filing":"0001179110-21-004223","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004223/edgar.xml","form_type":"4"}},{"id":2757367,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-05T20:17:30.000Z","date":"2021-04-05","kind":"exercise","acquired":true,"shares":1875,"price":41.64,"value":78075.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":11436,"source":{"system":"sec-edgar","filing":"0001179110-21-004223","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004223/edgar.xml","form_type":"4"}},{"id":2757366,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-05T20:17:30.000Z","date":"2021-04-05","kind":"exercise","acquired":true,"shares":5000,"price":35.34,"value":176700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":9561,"source":{"system":"sec-edgar","filing":"0001179110-21-004223","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004223/edgar.xml","form_type":"4"}},{"id":2760795,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-04-02T18:00:25.000Z","date":"2021-04-01","kind":"exercise","acquired":false,"shares":2050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares of common stock underlying this stock option award vested in full on the one year anniversary of the grant date."}],"balance_after":6135,"derivative":{"exercise_price":52.99,"expiration_date":"2030-01-22","underlying":"Common Stock","underlying_shares":2050},"source":{"system":"sec-edgar","filing":"0001179110-21-004119","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004119/edgar.xml","form_type":"4"}},{"id":2760794,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-04-02T18:00:25.000Z","date":"2021-04-01","kind":"exercise","acquired":false,"shares":1875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares of common stock underlying this stock option award vested in full on the one year anniversary of the grant date."}],"balance_after":5625,"derivative":{"exercise_price":41.64,"expiration_date":"2029-01-25","underlying":"Common Stock","underlying_shares":1875},"source":{"system":"sec-edgar","filing":"0001179110-21-004119","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004119/edgar.xml","form_type":"4"}},{"id":2760793,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-04-02T18:00:25.000Z","date":"2021-04-01","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of common stock underlying this stock option award vested in equal quarterly installments over the first three years after the grant."}],"balance_after":15000,"derivative":{"exercise_price":35.34,"expiration_date":"2027-11-15","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001179110-21-004119","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004119/edgar.xml","form_type":"4"}},{"id":2760792,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-02T18:00:25.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":941,"price":137.92,"value":129782.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.77 to $138.16 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4."}],"balance_after":4561,"source":{"system":"sec-edgar","filing":"0001179110-21-004119","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004119/edgar.xml","form_type":"4"}},{"id":2760791,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-02T18:00:25.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":3796,"price":136.92,"value":519748.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.74 to $137.36 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4."}],"balance_after":5502,"source":{"system":"sec-edgar","filing":"0001179110-21-004119","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004119/edgar.xml","form_type":"4"}},{"id":2760790,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-02T18:00:25.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":2987,"price":136.22,"value":406889.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.72 to $136.64 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":9298,"source":{"system":"sec-edgar","filing":"0001179110-21-004119","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004119/edgar.xml","form_type":"4"}},{"id":2760789,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-02T18:00:25.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":1201,"price":134.54,"value":161582.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.10 to $135.05 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":12285,"source":{"system":"sec-edgar","filing":"0001179110-21-004119","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004119/edgar.xml","form_type":"4"}},{"id":2760788,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-02T18:00:25.000Z","date":"2021-04-01","kind":"exercise","acquired":true,"shares":2050,"price":52.99,"value":108629.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":13486,"source":{"system":"sec-edgar","filing":"0001179110-21-004119","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004119/edgar.xml","form_type":"4"}},{"id":2760787,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-02T18:00:25.000Z","date":"2021-04-01","kind":"exercise","acquired":true,"shares":1875,"price":41.64,"value":78075.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":11436,"source":{"system":"sec-edgar","filing":"0001179110-21-004119","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004119/edgar.xml","form_type":"4"}},{"id":2760786,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-02T18:00:25.000Z","date":"2021-04-01","kind":"exercise","acquired":true,"shares":5000,"price":35.34,"value":176700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":9561,"source":{"system":"sec-edgar","filing":"0001179110-21-004119","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004119/edgar.xml","form_type":"4"}},{"id":2827647,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-02T02:05:56.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":16400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended."}],"balance_after":16400,"derivative":{"exercise_price":11.19,"expiration_date":"2031-02-24","underlying":"Common Stock","underlying_shares":16400},"source":{"system":"sec-edgar","filing":"0001209191-21-015513","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919121015513/doc4.xml","form_type":"4"}},{"id":2827646,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-02T02:05:56.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":8200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of restricted stock units (\"RSUs\"). The RSUs will fully vest on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP, as amended\")), through such date and subject to acceleration as provided in the 2018 EIP, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 1,667 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on June 26, 2018 representing the final remaining vesting tranche from such RSU grant with such RSUs vesting on June 26, 2021; and (b) 10,000 shares of common stock issuable upon settlement of RSUs subject to Reporting Person's May 18, 2020 RSU grant that will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the Issuer's 2021 annual stockholders meeting.  The vesting of all such RSUs is subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended."}],"balance_after":25700,"source":{"system":"sec-edgar","filing":"0001209191-21-015513","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919121015513/doc4.xml","form_type":"4"}},{"id":2829157,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Employee Stock Options (Right to Buy)","published_at":"2021-02-26T22:15:59.000Z","date":"2021-02-24","kind":"grant","acquired":true,"shares":11765,"price":93.49,"value":1099909.85,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Vests in three equal installments beginning on the day prior to the anniversary date of the grant."}],"balance_after":11765,"derivative":{"exercise_price":93.49,"expiration_date":"2028-02-23","underlying":"Common Stock","underlying_shares":11765},"source":{"system":"sec-edgar","filing":"0001367644-21-000044","document":"wf-form4_161437771751742.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764421000044/wf-form4_161437771751742.xml","form_type":"4"}},{"id":2829156,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-26T22:15:59.000Z","date":"2021-02-24","kind":"grant","acquired":true,"shares":2941,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA margin calculated on a cumulative basis over the three-year period beginning January 1, 2021 and ending December 31, 2023, as certified by the Compensation Committee following the performance period.  The amount reported is based on the target performance payout factor, or 100%."}],"balance_after":12193,"source":{"system":"sec-edgar","filing":"0001367644-21-000044","document":"wf-form4_161437771751742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764421000044/wf-form4_161437771751742.xml","form_type":"4"}},{"id":2829155,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-26T22:15:59.000Z","date":"2021-02-24","kind":"grant","acquired":true,"shares":2942,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement."}],"balance_after":9252,"source":{"system":"sec-edgar","filing":"0001367644-21-000044","document":"wf-form4_161437771751742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764421000044/wf-form4_161437771751742.xml","form_type":"4"}},{"id":2885154,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-02-02T18:52:47.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":3222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date."}],"balance_after":3222,"derivative":{"exercise_price":115.53,"expiration_date":"2031-01-29","underlying":"Common Stock","underlying_shares":3222},"source":{"system":"sec-edgar","filing":"0001179110-21-001113","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021001113/edgar.xml","form_type":"4"}},{"id":2885153,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-02T18:52:47.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":1622,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4561,"source":{"system":"sec-edgar","filing":"0001179110-21-001113","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021001113/edgar.xml","form_type":"4"}},{"id":3110955,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-15T21:15:49.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":58246,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest and become exercisable one year from the grant date."}],"balance_after":58246,"derivative":{"exercise_price":2.73,"expiration_date":"2030-06-11","underlying":"Common Stock","underlying_shares":58246},"source":{"system":"sec-edgar","filing":"0001209191-20-036849","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919120036849/doc4.xml","form_type":"4"}},{"id":3110954,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-15T21:15:49.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":30220,"price":2.73,"value":82500.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest one year from the grant date."}],"balance_after":54193,"source":{"system":"sec-edgar","filing":"0001209191-20-036849","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919120036849/doc4.xml","form_type":"4"}},{"id":3125207,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-03T20:30:18.000Z","date":"2020-05-18","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended."}],"balance_after":20000,"derivative":{"exercise_price":10.46,"expiration_date":"2030-05-17","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-20-034029","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919120034029/doc4a.xml","form_type":"4/A","original_submission_date":"2020-05-20"}},{"id":3125206,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-03T20:30:18.000Z","date":"2020-05-18","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of restricted stock units (\"RSUs\"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP, as amended\")), through such date and subject to acceleration as provided in the 2018 EIP, as amended."},{"field":"shares","element":"transactionShares","label":"F2","text":"This Form 4/A is being filed solely to correct the stated grant amounts which were erroneously reported on Form 4 filed on behalf of the Reporting Person on May 20, 2020.  Pursuant to the 2018 EIP, as amended, and the Automatic Grant Program for Non-Employee Directors thereunder, the annual grant amounts increased effective with the approval of the 2018 EIP, as amended, by the stockholders of the Issuer on May 18, 2020.  Such previously filed Form 4 incorrectly stated grant amounts pursuant to the Automatic Grant Program for Non-Employee Directors prior to such amendment and restatement of the 2018 Equity Incentive Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 3,333 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on June 26, 2018 representing two remaining vesting tranches from such RSU grant.  Such RSUs vest with respect to 1,666 shares on June 26, 2020 and 1,667 shares on June 26, 2021, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended) through such dates and subject to acceleration as provided in the 2018 EIP, as amended."}],"balance_after":17500,"source":{"system":"sec-edgar","filing":"0001209191-20-034029","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919120034029/doc4a.xml","form_type":"4/A","original_submission_date":"2020-05-20"}},{"id":3141424,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-20T21:21:43.000Z","date":"2020-05-18","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date."}],"balance_after":15000,"derivative":{"exercise_price":10.46,"expiration_date":"2030-05-17","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-030965","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919120030965/doc4.xml","form_type":"4"}},{"id":3141423,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-20T21:21:43.000Z","date":"2020-05-18","kind":"grant","acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of restricted stock units (\"RSUs\"). The RSUs will fully vest on the earlier of (x) May 18, 2021, (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,333 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on June 26, 2018 representing two remaining vesting tranches from such RSU grant.  Such RSUs vest with respect to 1,666 shares on June 26, 2020 and 1,667 shares on June 26, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such dates."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-20-030965","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919120030965/doc4.xml","form_type":"4"}},{"id":3302769,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2020-01-24T19:32:54.000Z","date":"2020-01-22","kind":"grant","acquired":true,"shares":8185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date."}],"balance_after":8185,"derivative":{"exercise_price":52.99,"expiration_date":"2030-01-22","underlying":"Common Stock","underlying_shares":8185},"source":{"system":"sec-edgar","filing":"0001179110-20-000790","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911020000790/edgar.xml","form_type":"4"}},{"id":3302768,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-24T19:32:54.000Z","date":"2020-01-22","kind":"grant","acquired":true,"shares":1377,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2939,"source":{"system":"sec-edgar","filing":"0001179110-20-000790","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911020000790/edgar.xml","form_type":"4"}},{"id":3490397,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-14T17:51:26.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":46729,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest and become exercisable one year from the grant date."}],"balance_after":46729,"derivative":{"exercise_price":2.92,"expiration_date":"2029-06-13","underlying":"Common Stock","underlying_shares":46729},"source":{"system":"sec-edgar","filing":"0001209191-19-037257","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119037257/doc4.xml","form_type":"4"}},{"id":3490396,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T17:51:26.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":23973,"price":2.92,"value":70001.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest one year from the grant date."}],"balance_after":23973,"source":{"system":"sec-edgar","filing":"0001209191-19-037257","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119037257/doc4.xml","form_type":"4"}},{"id":3493229,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-12T21:09:53.000Z","date":"2019-06-10","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date."}],"balance_after":15000,"derivative":{"exercise_price":9.38,"expiration_date":"2029-06-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-19-036443","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919119036443/doc4.xml","form_type":"4"}},{"id":3493228,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-12T21:09:53.000Z","date":"2019-06-10","kind":"grant","acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of restricted stock units (\"RSUs\"). The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to the 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,000 shares of common stock issuable upon settlement of restricted stock units (\"RSUs\") granted to the Reporting Person on June 26, 2018. The RSUs will vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001209191-19-036443","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919119036443/doc4.xml","form_type":"4"}},{"id":3615024,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-03-05T18:02:38.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents initial grant of options, given to each director upon becoming a member of the board of directors, to purchase shares of common stock, par value of $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in equal quarterly installments over three years from the date of grant."}],"balance_after":20000,"derivative":{"exercise_price":3.72,"expiration_date":"2029-03-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-19-016881","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119016881/doc4.xml","form_type":"4"}},{"id":3683706,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2019-01-29T17:49:21.000Z","date":"2019-01-25","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date."}],"balance_after":7500,"derivative":{"exercise_price":41.64,"expiration_date":"2029-01-25","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001179110-19-001064","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911019001064/edgar.xml","form_type":"4"}},{"id":3683705,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-01-29T17:49:21.000Z","date":"2019-01-25","kind":"grant","acquired":true,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1562,"source":{"system":"sec-edgar","filing":"0001179110-19-001064","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911019001064/edgar.xml","form_type":"4"}},{"id":3881661,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-28T23:33:16.000Z","date":"2018-06-26","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer.  The shares subject to the option vest in 36 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 36-month period measured from the grant date."}],"balance_after":30000,"derivative":{"exercise_price":15.65,"expiration_date":"2028-06-25","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-18-039973","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919118039973/doc4.xml","form_type":"4"}},{"id":3881660,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-28T23:33:16.000Z","date":"2018-06-26","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of restricted stock units (\"RSUs\").  The RSUs will vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001209191-18-039973","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919118039973/doc4.xml","form_type":"4"}},{"id":4007841,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CMO"}}],"security":"Ordinary Shares","published_at":"2018-03-07T21:11:16.000Z","date":"2018-03-05","kind":"tax_withholding","acquired":false,"shares":648,"price":143.39,"value":92916.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units."}],"balance_after":28474,"source":{"system":"sec-edgar","filing":"0001232524-18-000062","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252418000062/edgardoc.xml","form_type":"4"}},{"id":4014375,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CMO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2018-03-05T21:30:47.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":19290,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 1, 2018, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":19290,"derivative":{"exercise_price":140.67,"expiration_date":"2028-02-29","underlying":"Ordinary Shares","underlying_shares":19290},"source":{"system":"sec-edgar","filing":"0001232524-18-000046","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252418000046/edgardoc.xml","form_type":"4"}},{"id":4014374,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CMO"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2018-03-05T21:30:47.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":710,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 1, 2018, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":710,"derivative":{"exercise_price":140.67,"expiration_date":"2028-02-29","underlying":"Ordinary Shares","underlying_shares":710},"source":{"system":"sec-edgar","filing":"0001232524-18-000046","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252418000046/edgardoc.xml","form_type":"4"}},{"id":4014373,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CMO"}}],"security":"Ordinary Shares","published_at":"2018-03-05T21:30:47.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2018, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years."}],"balance_after":29122,"source":{"system":"sec-edgar","filing":"0001232524-18-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252418000046/edgardoc.xml","form_type":"4"}},{"id":4014540,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2018-03-05T17:23:08.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":1875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date."}],"balance_after":1875,"derivative":{"exercise_price":40.61,"expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":1875},"source":{"system":"sec-edgar","filing":"0001179110-18-003511","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911018003511/edgar.xml","form_type":"4"}},{"id":4014539,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-05T17:23:08.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":312,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":312,"source":{"system":"sec-edgar","filing":"0001179110-18-003511","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911018003511/edgar.xml","form_type":"4"}},{"id":4026777,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CMO"}}],"security":"Ordinary Shares","published_at":"2018-02-28T22:27:47.000Z","date":"2018-02-26","kind":"tax_withholding","acquired":false,"shares":525,"price":147.44,"value":77406.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 59 ordinary shares acquired on May 31, 2017 and 61 ordinary shares acquired on November 30, 2017 under a Section 423 Employee Stock Purchase Plan."}],"balance_after":21122,"source":{"system":"sec-edgar","filing":"0001232524-18-000029","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252418000029/edgardoc.xml","form_type":"4"}},{"id":4062252,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2018-02-13T16:56:47.000Z","date":"2018-02-13","kind":"disposition_to_issuer","acquired":false,"shares":30000,"price":7.05,"value":211500.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the \"Option Spread\"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":10.95,"expiration_date":"2027-07-15","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001171843-18-001109","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184318001109/formfour.xml","form_type":"4"}},{"id":4162010,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2017-11-15T16:22:13.000Z","date":"2017-11-15","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in equal quarterly installments over the first three years after the grant."}],"balance_after":20000,"derivative":{"exercise_price":35.34,"expiration_date":"2027-11-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001179110-17-014159","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911017014159/edgar.xml","form_type":"4"}},{"id":4322389,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CMO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-05-13T00:52:54.000Z","date":"2017-05-11","kind":"grant","acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, May 11, 2017, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":2500,"derivative":{"exercise_price":155.18,"expiration_date":"2027-05-10","underlying":"Ordinary Shares","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001639637-17-000004","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000163963717000004/edgardoc.xml","form_type":"4"}},{"id":4322388,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CMO"}}],"security":"Ordinary Shares","published_at":"2017-05-13T00:52:54.000Z","date":"2017-05-11","kind":"grant","acquired":true,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of June 5, 2017, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years."}],"balance_after":21527,"source":{"system":"sec-edgar","filing":"0001639637-17-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000163963717000004/edgardoc.xml","form_type":"4"}},{"id":4322387,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CMO"}}],"security":"Ordinary Shares","published_at":"2017-05-13T00:52:54.000Z","date":"2017-05-11","kind":"tax_withholding","acquired":false,"shares":641,"price":155.18,"value":99470.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units."}],"balance_after":20527,"source":{"system":"sec-edgar","filing":"0001639637-17-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000163963717000004/edgardoc.xml","form_type":"4"}}],"next_cursor":"2017-05-13T00:52:54.000000Z,4322387"}